Table 2.
Ongoing clinical trials of BETi and BET-PROTAC in hematologic tumors (from www.clinicaltrials.gov, last update).
| Compound | Sponsor | Status | Clinical phase | Diseases | Estimated Enrollment | Identifier | Estimated completion date |
|---|---|---|---|---|---|---|---|
| PLX51107 | Hannah Choe | Not yet recruiting | Phase 1 Phase 2 |
Steroid Refractory GVHD | 34 | NCT04910152 | December 31, 2024 |
| CPI-0610 | Constellation Pharmaceuticals | Recruiting | Phase 1 Phase 2 |
Hematological Malignancies, Myelofibrosis | 341 | NCT02158858 | December 31, 2022 |
| INCB057643 | Incyte Corporation | Recruiting | Phase 1 | Myelofibrosis and Other Advanced Myeloid Neoplasms | 39 | NCT04279847 | November 11, 2024 |
| BMS-986158 | Dana-Farber Cancer Institute | Recruiting | Phase 1 | Childhood Lymphoma | 34 | NCT03936465 | July 10, 2024 |
| ZEN003694 | National Cancer Institute (NCI) | Recruiting | Phase 1 Phase 2 |
Advanced Lymphoma | 30 | NCT05053971 | May 1, 2023 |
| CC-95775 | Celgene | Active, not recruiting | Phase 1 | Non-Hodgkin Lymphoma | 24 | NCT04089527 | October 31, 2021 |
| CPI-0610 | Constellation Pharmaceuticals | Recruiting | Phase 3 | Myelofibrosis | 310 | NCT04603495 | September 2023 |
| PLX51107 | M.D. Anderson Cancer Center | Recruiting | Phase 1 | AML, MDS, MPN | 32 | NCT04022785 | December 31, 2022 |